Asceniv (intravenous immunoglobulin) / ADMA Biologics  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Asceniv (intravenous immunoglobulin) / ADMA Biologics
NCT05070455: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

Recruiting
4
12
US
Asceniv™
ADMA Biologics, Inc.
Primary Immune Deficiency
03/23
06/23

Download Options